GlassScriptPhysician profile
Mark R Hofmeyer
NPI 1194926071
$10,480.87
in general payments reported to CMS, 2019-2025
20 companies · $1,108 in 2025
The $1,108 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.84 · 2020: $34.27 · 2022: $290 · 2023: $823 · 2024: $8,183 · 2025: $1,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,600 · Food and Beverage: $2,480 · Travel and Lodging: $2,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,600.00 |
| Food and Beverage | $2,480.12 |
| Travel and Lodging | $2,033.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuwellis, INC. | $7,633.97 | 2024 | Aquadex Smartflow Console |
| Abbott Laboratories | $1,477.46 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $171.08 | 2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.29 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $151.32 | 2022-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $137.19 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $120.83 | 2024-2025 | Amvuttra, Onpattro |
| Novo Nordisk INC | $102.35 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $93.48 | 2023-2025 | Lifevest |
| Amgen INC. | $69.25 | 2022-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $58.23 | 2024-2025 | Camzyos |
| Pfizer INC. | $56.66 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $45.59 | 2022-2025 | Farxiga |
| Cvrx, INC. | $45.49 | 2024 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $43.99 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $40.38 | 2025 | Opsumit |
| Scpharmaceuticals INC. | $30.43 | 2025 | |
| Ancora Heart, INC. | $24.78 | 2025 | Accucinch |
| Medtronic Vascular, INC. | $23.10 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hofmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.